Oncology Biosimilars Market Size, Share, Trends, Growth Outlook

Oncology Biosimilars Market is estimated to increase at a growth rate of 9.3% CAGR over the forecast period from 2024 to 2030.

The global Oncology Biosimilars Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer, Others), By Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, Others), By Route of Administration (Intravenous, Subcutaneous, Others), By End-User (Hospitals, Specialty Clinics, Homecare, Others).

An Introduction to Oncology Biosimilars Market in 2024

The Oncology Biosimilars Market is witnessing rapid growth and adoption in 2024, fueled by increasing demand for cost-effective alternatives to originator biologic drugs and the expanding oncology therapeutic landscape. With biologic therapies playing a pivotal role in cancer treatment, biosimilars offer a promising opportunity to enhance patient access to high-quality, affordable cancer care while driving healthcare cost containment efforts. The market is characterized by the development and commercialization of biosimilar versions of key oncology biologics, including monoclonal antibodies, growth factors, and cytokine inhibitors, with several products gaining regulatory approval and market penetration worldwide. Moreover, there is growing acceptance of biosimilars among oncologists, healthcare payers, and patients, supported by robust clinical evidence demonstrating comparable efficacy, safety, and immunogenicity to reference biologics. As the oncology biosimilars market continues to mature, it holds potential for significant savings in cancer healthcare expenditure and improved patient access to life-saving treatments, underscoring its pivotal role in advancing global cancer care initiatives.

Oncology Biosimilars Market Competitive Landscape

The global Oncology Biosimilars Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Oncology Biosimilars Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Oncology Biosimilars Industry include- Allergan, Amneal Pharmaceuticals LLC , Apotex Inc, Aurobindo Pharma, BIOCAD, Bristol-Myers Squibb Company, Cipla Inc, Eli Lilly and Co., Endo International plc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd, Lupin, Mylan N.V., Novartis AG, Pfizer Inc, Sanofi S.A., Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd, Zydus Cadila.

Oncology Biosimilars Market Trend: Growing Adoption of Biosimilars in Oncology

In the Oncology Biosimilars market, a prominent trend is the growing adoption of biosimilars as cost-effective alternatives to originator biologics. Biosimilars are highly similar versions of approved biologic drugs with no clinically meaningful differences in terms of safety, efficacy, and quality. As patents expire for originator biologics used in oncology, such as monoclonal antibodies targeting cancer cells and supportive care agents, biosimilar manufacturers are capitalizing on the opportunity to develop and commercialize biosimilar versions at lower costs. The increasing demand for affordable cancer treatments, coupled with regulatory pathways facilitating biosimilar approval and market access, has fueled the adoption of biosimilars by healthcare providers, payers, and patients. Additionally, clinical studies demonstrating comparable efficacy and safety profiles between biosimilars and reference biologics have bolstered confidence in their use in oncology practice. As healthcare systems strive to contain costs while maintaining quality cancer care, the growing adoption of biosimilars represents a significant trend shaping the Oncology Biosimilars market.

Oncology Biosimilars Market Driver: Cost Containment and Access to Cancer Therapies

The primary market driver for Oncology Biosimilars is cost containment and improved access to cancer therapies. Cancer treatment costs continue to rise, posing financial challenges for healthcare systems, payers, and patients worldwide. Biologic drugs represent a significant portion of cancer treatment expenditures, making them a target for cost-saving strategies. Biosimilars offer the potential to reduce healthcare spending on oncology treatments by providing more affordable alternatives to originator biologics, thus easing the financial burden on healthcare budgets and improving access to cancer therapies for patients. Additionally, biosimilar competition has the potential to drive down prices of originator biologics, further lowering treatment costs and expanding access to innovative cancer treatments. The cost-saving benefits of biosimilars are particularly relevant in oncology, where the use of biologic drugs is prevalent across a wide range of cancer types and treatment settings. As healthcare stakeholders prioritize value-based care and cost-effective treatment options, the market demand for Oncology Biosimilars continues to grow, driven by the imperative to contain costs while ensuring access to high-quality cancer care for patients.

Oncology Biosimilars Market Opportunity: Expansion of Biosimilar Portfolio and Market Share

An emerging opportunity in the Oncology Biosimilars market lies in the expansion of biosimilar portfolios and market share. While biosimilars have gained traction in certain oncology indications, such as supportive care agents like granulocyte colony-stimulating factors (G-CSFs) and erythropoiesis-stimulating agents (ESAs), there is potential for growth in other areas of oncology, including monoclonal antibodies targeting cancer cells and biologic therapies for immune checkpoint inhibition. By developing biosimilar versions of blockbuster cancer drugs and securing regulatory approvals for additional indications, biosimilar manufacturers can expand their market presence and compete more effectively with originator biologics. Furthermore, strategic partnerships, licensing agreements, and distribution networks can facilitate the global commercialization of biosimilars, enabling broader access to affordable cancer treatments in diverse healthcare markets. Additionally, initiatives to educate healthcare providers, patients, and policymakers about the safety, efficacy, and cost-saving benefits of biosimilars can help overcome barriers to adoption and drive market growth. Collaborative efforts between biosimilar manufacturers, regulatory authorities, healthcare organizations, and patient advocacy groups are essential for realizing the full potential of Oncology Biosimilars and maximizing their impact on cancer care delivery and patient outcomes.

Oncology Biosimilars Market Share Analysis: Monoclonal Antibodies drug class is the fastest growing market segment over the forecast period to 2030

The fastest growing segment in the Oncology Biosimilars Market is the Monoclonal Antibodies drug class. This growth is primarily driven by the increasing adoption of biosimilar monoclonal antibodies for the treatment of various cancers, including breast cancer, lung cancer, colorectal cancer, and blood cancer. Monoclonal antibodies offer targeted therapy with fewer side effects compared to traditional chemotherapy, leading to improved patient outcomes and quality of life. The rising demand for cost-effective cancer treatments, coupled with patent expirations of key biologic drugs, encourages the development and market penetration of biosimilar monoclonal antibodies. Additionally, advancements in biotechnology and regulatory approvals for biosimilars contribute to their rapid growth within hospitals, specialty clinics, homecare settings, and across various distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies.

Oncology Biosimilars Market Segmentation

By Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Blood Cancer
Others
By Drug Class
Monoclonal Antibodies
Granulocyte Colony-Stimulating Factor
Others
By Route of Administration
Intravenous
Subcutaneous
Others
By End-User
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Oncology Biosimilars Companies

Allergan
Amneal Pharmaceuticals LLC
Apotex Inc
Aurobindo Pharma
BIOCAD
Bristol-Myers Squibb Company
Cipla Inc
Eli Lilly and Co.
Endo International plc
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Glenmark Pharmaceuticals Ltd
Lupin
Mylan N.V.
Novartis AG
Pfizer Inc
Sanofi S.A.
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Co. Ltd
Teva Pharmaceutical Industries Ltd
Zydus Cadila
* List not Exhaustive

Reasons to Buy the Oncology Biosimilars Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Oncology Biosimilars Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Oncology Biosimilars Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Oncology Biosimilars Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Oncology Biosimilars Market Size Outlook, $ Million, 2021 to 2030
3.2 Oncology Biosimilars Market Outlook by Type, $ Million, 2021 to 2030
3.3 Oncology Biosimilars Market Outlook by Product, $ Million, 2021 to 2030
3.4 Oncology Biosimilars Market Outlook by Application, $ Million, 2021 to 2030
3.5 Oncology Biosimilars Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Oncology Biosimilars Industry
4.2 Key Market Trends in Oncology Biosimilars Industry
4.3 Potential Opportunities in Oncology Biosimilars Industry
4.4 Key Challenges in Oncology Biosimilars Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Oncology Biosimilars Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Oncology Biosimilars Market Outlook by Segments
7.1 Oncology Biosimilars Market Outlook by Segments, $ Million, 2021- 2030
By Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Blood Cancer
Others
By Drug Class
Monoclonal Antibodies
Granulocyte Colony-Stimulating Factor
Others
By Route of Administration
Intravenous
Subcutaneous
Others
By End-User
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
8 North America Oncology Biosimilars Market Analysis and Outlook To 2030
8.1 Introduction to North America Oncology Biosimilars Markets in 2024
8.2 North America Oncology Biosimilars Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Oncology Biosimilars Market size Outlook by Segments, 2021-2030
By Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Blood Cancer
Others
By Drug Class
Monoclonal Antibodies
Granulocyte Colony-Stimulating Factor
Others
By Route of Administration
Intravenous
Subcutaneous
Others
By End-User
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
9 Europe Oncology Biosimilars Market Analysis and Outlook To 2030
9.1 Introduction to Europe Oncology Biosimilars Markets in 2024
9.2 Europe Oncology Biosimilars Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Oncology Biosimilars Market Size Outlook by Segments, 2021-2030
By Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Blood Cancer
Others
By Drug Class
Monoclonal Antibodies
Granulocyte Colony-Stimulating Factor
Others
By Route of Administration
Intravenous
Subcutaneous
Others
By End-User
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
10 Asia Pacific Oncology Biosimilars Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Oncology Biosimilars Markets in 2024
10.2 Asia Pacific Oncology Biosimilars Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Oncology Biosimilars Market size Outlook by Segments, 2021-2030
By Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Blood Cancer
Others
By Drug Class
Monoclonal Antibodies
Granulocyte Colony-Stimulating Factor
Others
By Route of Administration
Intravenous
Subcutaneous
Others
By End-User
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
11 South America Oncology Biosimilars Market Analysis and Outlook To 2030
11.1 Introduction to South America Oncology Biosimilars Markets in 2024
11.2 South America Oncology Biosimilars Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Oncology Biosimilars Market size Outlook by Segments, 2021-2030
By Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Blood Cancer
Others
By Drug Class
Monoclonal Antibodies
Granulocyte Colony-Stimulating Factor
Others
By Route of Administration
Intravenous
Subcutaneous
Others
By End-User
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
12 Middle East and Africa Oncology Biosimilars Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Oncology Biosimilars Markets in 2024
12.2 Middle East and Africa Oncology Biosimilars Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Oncology Biosimilars Market size Outlook by Segments, 2021-2030
By Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Blood Cancer
Others
By Drug Class
Monoclonal Antibodies
Granulocyte Colony-Stimulating Factor
Others
By Route of Administration
Intravenous
Subcutaneous
Others
By End-User
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Allergan
Amneal Pharmaceuticals LLC
Apotex Inc
Aurobindo Pharma
BIOCAD
Bristol-Myers Squibb Company
Cipla Inc
Eli Lilly and Co.
Endo International plc
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Glenmark Pharmaceuticals Ltd
Lupin
Mylan N.V.
Novartis AG
Pfizer Inc
Sanofi S.A.
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Co. Ltd
Teva Pharmaceutical Industries Ltd
Zydus Cadila
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Cervical Cancer
Blood Cancer
Others
By Drug Class
Monoclonal Antibodies
Granulocyte Colony-Stimulating Factor
Others
By Route of Administration
Intravenous
Subcutaneous
Others
By End-User
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others